Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac

Chris Ka Pun Mok, Samuel M.S. Cheng, Chunke Chen, Karen Yiu, Tat-On Chan, Kiu Cheung Lai, Kwun Cheung Ling, Yuanxin Sun, Lun Lai Ho, Malik Peiris, David S Hui
doi: https://doi.org/10.1101/2021.11.02.21265843
Chris Ka Pun Mok
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
2Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel M.S. Cheng
4School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunke Chen
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
2Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Yiu
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tat-On Chan
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiu Cheung Lai
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
2Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kwun Cheung Ling
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuanxin Sun
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
2Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lun Lai Ho
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malik Peiris
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
4School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: malik@hku.hk dschui@cuhk.edu.hk
David S Hui
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
6Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: malik@hku.hk dschui@cuhk.edu.hk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Poor immunogenicity and antibody waning were found in vaccinees of CoronaVac. There is lack of randomized controlled trial (RCT) data to compare the immunogenicity and safety of schedules using homologous and heterologous vaccine as a booster dose.

Methods We randomly assigned adults who had received 2 doses of CoronaVac with low antibody response to receive an additional booster dose of either BNT162b2 or CoronaVac. The local and systemic adverse reactions were recorded. Levels of SARS-CoV-2 neutralizing and spike binding antibody in plasma were measured.

Findings At one month after the third dose of vaccine, BNT162b2 vaccines elicited significantly higher surrogate virus neutralizing test (sVNT), spike receptor binding, spike N terminal domain binding, spike S2 domain binding levels than CoronaVac. More participants from the BNT162b2 group reported injection site pain and swelling as well as fatigue and muscle pain than those who received CoronaVac as the third dose. The mean results of the sVNT against the wild type, beta, gamma and delta variants in the BNT162b2 boosted group was 96.83%, 92.29%, 92.51% and 95.33% respectively which were significantly higher than the CoronaVac boosted group (Wild type: 57.75%; Beta: 38.79 %; Gamma: 32.22%; Delta: 48.87%)

Conclusion Our RCT study shows that BNT162b2 booster dose for those people who poorly responded to the previous vaccination of CoronaVac is significantly more immunogenic than a CoronaVac booster. BNT162b2 also elicits higher levels of SARS-CoV-2 specific neutralizing antibodies to different variants of concern. The adverse reactions were only mild and short-lived.

Scientific Knowledge on the Subject Poor immunogenicity and antibody waning were found in vaccinees of CoronaVac. There is lack of randomized controlled trial (RCT) data to compare the immunogenicity and safety of schedules using homologous and heterologous vaccine as a booster dose.

What This Study Adds to the Field Our RCT study shows that BNT162b2 booster dose for those people who poorly responded to the previous vaccination of CoronaVac is significantly more immunogenic than a CoronaVac booster. The adverse reactions were only mild and short-lived.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04611243

Funding Statement

This research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003; COVID190126) (CKPM, MP and DSH), Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government (NRF-2018M3A9H4055203) (CKPM), US National Institutes of Health (contract no. U01-Grant AI151810) (MP), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (CKPM and MP), RGC theme-based research schemes (T11-712/19-N and T11-705/21-N) (DSH, MP).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref no: 2020.229) and all participants provided written consent. This clinical trial has been registered at ClinicalTrials.gov with identifier NCT04611243

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding source: This research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003; COVID190126) (CKPM, MP and DSH), Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government (NRF-2018M3A9H4055203) (CKPM), US National Institutes of Health (contract no. U01-Grant AI151810) (MP), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (CKPM and MP), RGC theme-based research schemes (T11-712/19-N and T11-705/21-N) (DSH, MP).

  • Conflicts of Interest: We declare no competing interests.

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 03, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac
Chris Ka Pun Mok, Samuel M.S. Cheng, Chunke Chen, Karen Yiu, Tat-On Chan, Kiu Cheung Lai, Kwun Cheung Ling, Yuanxin Sun, Lun Lai Ho, Malik Peiris, David S Hui
medRxiv 2021.11.02.21265843; doi: https://doi.org/10.1101/2021.11.02.21265843
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac
Chris Ka Pun Mok, Samuel M.S. Cheng, Chunke Chen, Karen Yiu, Tat-On Chan, Kiu Cheung Lai, Kwun Cheung Ling, Yuanxin Sun, Lun Lai Ho, Malik Peiris, David S Hui
medRxiv 2021.11.02.21265843; doi: https://doi.org/10.1101/2021.11.02.21265843

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (419)
  • Anesthesia (97)
  • Cardiovascular Medicine (894)
  • Dentistry and Oral Medicine (166)
  • Dermatology (101)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
  • Epidemiology (8744)
  • Forensic Medicine (4)
  • Gastroenterology (403)
  • Genetic and Genomic Medicine (1844)
  • Geriatric Medicine (175)
  • Health Economics (386)
  • Health Informatics (1281)
  • Health Policy (642)
  • Health Systems and Quality Improvement (488)
  • Hematology (206)
  • HIV/AIDS (387)
  • Infectious Diseases (except HIV/AIDS) (10519)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (216)
  • Neurology (1744)
  • Nursing (100)
  • Nutrition (264)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (457)
  • Oncology (959)
  • Ophthalmology (279)
  • Orthopedics (107)
  • Otolaryngology (174)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (262)
  • Pediatrics (553)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1836)
  • Public and Global Health (3962)
  • Radiology and Imaging (649)
  • Rehabilitation Medicine and Physical Therapy (340)
  • Respiratory Medicine (532)
  • Rheumatology (214)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (165)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (105)
  • Urology (78)